ArticleOncotarget2016

Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer.

Samer Alzoubi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.